Five questions about method validation every cardiovascular disease team should ask

Abstract

Longitudinal data show that variability between operators remains a key limitation, a finding echoed by several independent groups. Longitudinal data show that threshold harmonization is still an open question, pending validation in prospective studies.

Longitudinal data show that pre-analytical factors account for a large share of observed variance, a finding echoed by several independent groups. Longitudinal data show that cost considerations continue to shape adoption in smaller units, and this trend is expected to continue.

Practical implications

Longitudinal data show that standardized reporting improves comparability between centers, although confirmatory data are still limited. Contrary to earlier assumptions, variability between operators remains a key limitation, and this trend is expected to continue.

Where the field is heading

When protocols are compared, cross-disciplinary review changes the initial assessment in a sizeable minority of cases, pending validation in prospective studies. Recent studies suggest that digital tooling shortens time-to-decision considerably, with meaningful differences between subgroups. Recent studies suggest that real-world registries complement randomized trial evidence, pending validation in prospective studies.

In multidisciplinary settings, patient selection criteria deserve closer scrutiny, particularly in resource-constrained settings. Across multiple cohorts, patient selection criteria deserve closer scrutiny, and this trend is expected to continue. Across multiple cohorts, integrating quantitative measures reduces subjective bias, as discussed in the accompanying commentary. Across multiple cohorts, variability between operators remains a key limitation, pending validation in prospective studies. Emerging evidence indicates that cross-disciplinary review changes the initial assessment in a sizeable minority of cases, which has direct implications for daily practice.